anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement. Total daily energy intake of 1200-2000 kcal/day were based on baseline weight, and for safety, no woman was provided with less than 1100 kcals/d and no man less than 1300 kcals/d. The energy of the intake calorie restricted diet per day was calculated based on the detailed composition of meals, such as rice, vegetables, eggs, pork, and beef, using the Chinese food composition tables. Our diets were cooked with traditional Chinese cooking methods such as boiling, stir-frying, and stewing. During the intervention, other lipid-lowering drugs were not allowed to intake supplement as it alters the outcome. Participants receive education or counseling by a dietitian for modulations of their caloric intake weekly.

The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d/week. Resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d/week, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d/week. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video. Patients who complete at least 80% of diet restriction and exercise were included in analysis. Calorie restricted diet and exercise group contain both the above intervention.
Patients will receive advice to walk as suggested by the guidelines. In particular, a team member will recommend patients to gather almost 30 minutes of walking at least 3 times per week; when the patient will face claudication pain, he/she will be allowed to rest, and restart walking as soon as possible. A daily log to be compiled will be provided to each patients to record the amount of walk performed.
OBJECTIVE: To evaluate studies related to pain management associated with arteriovenous fistula cannulation among children.
METHODS: The systematic review comprised literature search on Embase, ProQuest, Science Direct, Scopus, SpringerLink and Wiley Online databases for studies published in English between 1998 and 2021. The search used key words, including pain management OR analgesia AND child OR paediatric AND haemodialysis OR dialysis AND arteriovenous fistula OR arteriovenous fistula cannulation OR fistula needle OR arteriovenous fistula insertion OR needle insertion. The quality of the studies was evaluated using the Joana Briggs Institute checklist. General characteristics of the and pain outcomes were noted.
RESULTS: Of the 2,877 studies initially identified, 8(0.27%) were analysed; 7(87.5%) quasi-experimental and 1(12.5%) randomised controlled trial. Overall, there were 283 participants aged 6-18 years. The strategies used for reducing arteriovenous fistula puncture-related pain among children undergoing haemodialysis included cryotherapy, lidocaine agents, virtual reality (VR), guided visualisation, balloon inflation, aromatherapy, and other programmed distractions. The strategies had a positive effect on reducing arteriovenous fistula cannulation-related pain among children.
CONCLUSION: Non-pharmacological pain management is an easier, simpler, inexpensive and more effective method of atraumatic care among children undergoing haemodialysis.
Patients receive HDMTX IV over 24 hours and vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
The instrumentation protocol with Protaper Universal rotary files was began with an S1 file with a brushing movement to the two thirds of the working length and then an SX file was introduced to the two thirds of the working length with a brushing movement Afterwards, S1, S2, F1, F2 files in mesial roots and F4 files in distal roots were used to the working length, respectively. Protaper F2 instrument was then used to complete the canal preparation in mesial roots and Protaper F4 instrument was used to complete the canal preparation in distal roots.
A modular linker includes an inorganic binding entity having an affinity for a substantially inorganic substance, and an organic binding entity capable of binding with an organic substance covalently bonded thereto. The modular linker is capable of being stored in a stable condition for later use. The modular linker may be synthesized by modifying the inorganic binding entity to be covalently bonded to an organic binding entity and storing the modular linker in an inert environment from about a day up to at least 1 week. The modular linker may be conjugated to an organic substance and to a substantially inorganic substance in substantially a 1 : 1 ratio. The modular linker may have more than one organic binding entity covalently bonded to an inorganic binding entity or vice-versa. Also, a particular modular linker may have an organic binding entity capable of binding with a nucleic acid sequence.
To individually improve vegetable intake.SOLUTION: The essence of the present invention lies in that selection basis of intake of vegetables is a result of skin measurement. An intake-of-vegetables improvement system 100 includes at least an output unit 110 and a processing unit 150 when defining the present invention in such an aspect. The output unit 110 is controlled by the processing unit 150, thereby content displayed by the output unit 110 is a sufficiency notification. In that time, the processing unit 150 refers to a skin state value of an individual. The sufficiency notification is given on a condition that the intake of vegetables of an individual is equal to or greater than a recommended intake of vegetables. An example of the skin state value is a skin carotenoid value.SELECTED DRAWING: Figure 7
The neurodevelopmental disorder Pitt Hopkins syndrome (PTHS) causes clinical symptoms similar to Rett syndrome (RTT) patients. However, RTT is caused by MECP2 mutations whereas mutations in the TCF4 gene lead to PTHS. The mechanistic commonalities underling these two disorders are unknown, but their shared symptomology suggest that convergent pathway-level disruption likely exists. We reprogrammed patient skin derived fibroblasts into induced neuronal progenitor cells. Interestingly, we discovered that MeCP2 levels were decreased in PTHS patient iNPCs relative to healthy controls and that both iNPCs and iAstrocytes displayed defects in function and differentiation in a mutation-specific manner. When Tcf4+/- mice were genetically crossed with mice overexpressing MeCP2, molecular and phenotypic defects were significantly ameliorated, underlining and important role of MeCP2 in PTHS pathology. Importantly, post-natal intracerebroventricular gene replacement therapy with adeno-associated viral vector serotype 9 (AAV9)-expressing MeCP2 (AAV9.P546.MeCP2) significantly improved iNPC and iAstrocyte function and effectively ameliorated histological and behavioral defects in Tcf4+/- mice. Combined, our data suggest a previously unknown role of MeCP2 in PTHS pathology and common pathways that might be affected in multiple neurodevelopmental disorders. Our work highlights potential novel therapeutic targets for PTHS, including upregulation of MeCP2 expression or its downstream targets or, potentially, MeCP2-based gene therapy.
The present invention describes the isolation and purification of histidine--tagged functional portions of intimin (his-tagged intimin or his-intimin), a protein associated with the ability of certain strains of pathogenic bacteria to adhere to epithelial cells. The invention further describes the use of intimin as an antigen to promote a protective immune response. In addition, the invention describes the combination of intimin with one or more other antigens and administration of the combination to promote a protective immune response against intimin and the one or more antigens. One aspect of the invention is the administration of intimin to target specific epithelial cells to promote a protective immune response to intimin proteins. Additional aspects of the invention include the use of intimin or intimin combined with one or more antigens and administration of the combination to target gastrointestinal mucosa and stimulate an immune response. Additionally, the invention describes administration of the combination of intimin combined with drugs, to provide a means for targeted delivery of drugs to specific epithelial cells. Other aspects of the invention include the production of antibodies directed against his-intimin and methods of using such antibodies to provide passive immune protection, and in an assay system.
Due to its unique structure, articular cartilage has limited abilities to undergo self-repair after injury. Additionally, the repair of articular cartilage after injury has always been a difficult problem in the field of sports medicine. Previous studies have shown that the therapeutic use of mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) has great potential for promoting cartilage repair. Recent studies have demonstrated that most transplanted stem cells undergo apoptosis in vivo, and the apoptotic EVs (ApoEVs) that are subsequently generated play crucial roles in tissue repair. Additionally, MSCs are known to exist under low-oxygen conditions in the physiological environment, and these hypoxic conditions can alter the functional and secretory properties of MSCs as well as their secretomes. This study aimed to investigate whether ApoEVs that are isolated from adipose-derived MSCs cultured under hypoxic conditions (hypoxic apoptotic EVs [H-ApoEVs]) exert greater effects on cartilage repair than those that are isolated from cells cultured under normoxic conditions. Through in vitro cell proliferation and migration experiments, we demonstrated that H-ApoEVs exerted enhanced effects on stem cell proliferation, stem cell migration, and bone marrow derived macrophages (BMDMs) M2 polarization compared to ApoEVs. Furthermore, we utilized a modified gelatine matrix/3D-printed extracellular matrix (ECM) scaffold complex as a carrier to deliver H-ApoEVs into the joint cavity, thus establishing a cartilage regeneration system. The 3D-printed ECM scaffold provided mechanical support and created a microenvironment that was conducive to cartilage regeneration, and the H-ApoEVs further enhanced the regenerative capacity of endogenous stem cells and the immunomodulatory microenvironment of the joint cavity; thus, this approach significantly promoted cartilage repair. In conclusion, this study confirmed that a ApoEVs delivery system based on a modified gelatine matrix/3D-printed ECM scaffold together with hypoxic preconditioning enhances the functionality of stem cell-derived ApoEVs and represents a promising approach for promoting cartilage regeneration.
Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
Cohort 2 retrospective/prospective study: patient not enrolled in the previous study (Fava et al 2019). The data for these patients will be collected since patient diagnosis to the end of the study.
Approximately 150,000 people are diagnosed with colorectal cancer in the United States each year. Forty to fifty thousand people eventually will develop metastatic colorectal cancer and 40,000 people die annually because of advanced or metastatic colorectal cancer. Cancer patients prefer oral therapy over intravenous therapy as palliative treatment if efficacy regarding response rate and response duration is not compromised. Therefore, development of a completely oral combination therapy that approximates or improves upon the clinical outcomes attained by the reference triple drug therapies should be a research priority. Compared with intravenous 5-fluourouracil/leucovorin as first-line treatment for metastatic colorectal cancer, oral capecitabine has demonstrated similar survival outcomes (approximately 12-13 months), response rates (15-20%), and response durations (4-5 months) in two multi-institutional international randomized phase III trials. Erlotinib (OSI-774, Tarceva) is an orally available inhibitor of human EGFR tyrosine kinase. The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human cancers including colorectal cancer. The principal goal of anticancer treatment with tyrosine kinase inhibitors such as erlotinib is to restore normal cellular growth by interrupting EGFR mediated cell proliferation and malignant The hypothesis of this phase II trial is that the unique mechanisms of action and non-overlapping toxicity profiles of capecitabine (Xeloda) and erlotinib will allow these drugs to be combined into a safe and tolerable regimen with better activity regarding response, response duration, and median survival than capecitabine alone in patients with previously untreated metastatic colorectal cancer.
PURPOSE:To provide a composition reactive with the sugar chain developed on cell surface due to human immunodeficiency virus(HIV) infection, thus useful as a diagnostic or medicine for AIDS, containing, as active ingredient, an antibody capable of recognizing the glycolipids derived from sea urchin. CONSTITUTION:The glycolipids derived from sea urchin are prepared by the established method, and administered to BALB/c mice to effect immunization. The splenocytes are then taken from the resulting mice and fused with established mouse myeloma cells using e.g. ethylene glycol as fusing agent, and the clones capable of producing antibody reactive with the above glycolipids are selected through screening, and the resulting hybridoma is provided with monoclonality through cloning using limiting dilution method, methyl cellulose method or soft agarose method. The resultant hybridoma is implanted into e.g. mice to produce monoclonal antibody in the ascites; the monoclonal antibody is purified to obtain the monoclonal antibody capable of recognizing the above glycolipids. This monoclonal antibody is made, as active ingredient, into a pharmaceutical to obtain the objective medicine composition for AIDS.
The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
This is a prospective, randomized, double-blind, placebo-controlled study to test the effects of canakinumab, an inhibitor of interleukin-1B, on vascular inflammation in individuals with coronary artery disease. Half of the trial population will have clonal hematopoiesis of indeterminate potential (CHIP) driven by mutations in TET2. Participants (total N=120) will be randomized 1:1 to receive canakinumab (n=60) versus placebo (n=60). Baseline assessment in all participants will include coronary CT angiography, and a subset of participants in each group (n=16 per group) will undergo SPECT imaging to assess macrophage-specific vascular inflammation. After randomization, participants will have injection/safety visits at Week 0, Week 12, Week 24, and Week 36. Repeat imaging assessments for vascular inflammation will occur during the Week 48 visit(s). Participants will undergo final study and safety assessments at Week 60. The primary endpoint is change in the fat attenuation index (FAI) as measured by coronary CT angiography between baseline and Week 48. Other key endpoints are change in macrophage-specific inflammation by SPECT between baseline and Week 48 and change in TET2 clonal variant allele fraction among participant with TET2 clonal hematopoiesis.
PURPOSE:To obtain a cosmetic containing an extract of Rosa plant and surfactant and effective on prevention of removal of hair, growth of hair, rearing of hair, acne, etc., and having excellent safety. CONSTITUTION:An extract of Rosa plant such as peach, Rosa rugasa, Rosa odorata, flower of Rosa odorata, R. coptophyllus Rosa centifolia, Sanguisorba afficinalis L. or Pseudocydonia siensis, anionic surfactant (e.g. laurylsulfuric acid sodium salt) and surfactant (e.g. dimethyllaurylamineoxide) other than the anionic surfactant and having a nitrogen atom in the molecule used are incorporated as essential ingredients into a cosmetic and the blend is prepared according to ordinary method to provide the aimed cosmetic. The extract of Rosa plant and surfactant are each blended at an amount of 0.005-10wt.% and 0.01-10wt.%, based on dried material. The anionic surfactant and surfactant other than the anionic surfactant having nitrogen atom in molecule are blended at molecular ratio of (20:1)-(1:20).
This invention discloses, as an article of manufacture, a capsule having a hollow interior and an enclosing wall, referred to as a membrane. The membrane is not soluble in water, but is permeable to water or an aqueous solution. The membrane is comprised of a first material and can also include a second material. When the membrane is comprised of the first material and the second material, then it is referred to as a composite material wherein the first material forms sporting matrix having the second material fixed in the matrix. The first material is a urethane/vinyl hybrid polymer and is not soluble in, reactive with or a solvent for the second material. The second material is a particulate solid, different from the first material, and is not soluble in, reactive with or a solvent for the first material. The capsule of this invention is useful to maintain in the hollow interior thereof a solid, water-soluble first chemical composition which is not soluble in, reactive with or a solvent for the enclosing wall of the capsule. In operation, the exterior of the capsule, having the first composition maintained in the interior thereof, is placed in contact with a water-soluble second chemical composition which is not soluble in, reactive with or a solvent for the enclosing wall of the capsule, but which is reactive with the first chemical composition.
NEW MATERIAL:A compound shown by the formula (Cys is cysteine; Ser is serine; Asp is aspartic acid; Leu is leucine; Thr is threonine; Val is valine; Gly is glycine; Lys is lysine; Gln is glutamine; Glu is glutamic acid; His is histidine; Tyr is tyrosine; Pro is proline; Arg is arginine; Ala is alanine) or its salt. Having the following chemical properties. White powder. Soluble in water, especially in acidic aqueous solution, insoluble in chloroform, benzene, etc. Molecular weight: 3,370.7. Physiological activity: 3,000-6,000MRCU/mg. USE:A lowering agent for Ca concentration in blood. PREPARATION:An extract is obtained from jaws of bird with an acidic aqueous solution. (A) A hydrophilic organic solvent is added to the extract, so that a high-molecular-weight substance is precipitated and removed, (B) a basic fraction is recovered with a cationic exchange resin, (C) a fraction having 3,000-4,000 molecular weight is recovered, or (D) a fraction having physiological activity like calcitonin is recovered by HLC (high-speed liquid chromatography).
A method of preparing polylactic acid microsphere is provided, including the following steps. A first solution is provided, including polylactic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres. The polylactic acid microspheres are collected. A polylactic acid microsphere is also provided. The polylactic acid microsphere is the accumulation of the polylactic acid. The polylactic acid microsphere has a smooth surface and a particle size distribution from 30μm to 100μm.
PURPOSE:To provide an antiulcer agent effective in increasing the blood flow rate in gastric mucosa and improving antiulcer effect, by combining 5- acylspiro[benzo(b)furan-2(3H),1'-cyclopropan]-3-one with an acid secretion- suppressing type antiulcer agent. CONSTITUTION:5-Acylspiro[benzo(b)furan-2(3H),1'-cyclopropan]-3-one and an acid secretion-suppressing type antiulcer agent (e.g. cimetidine, famotidine, pirenzepine, etc.) are used as active components of the objective agent. The former component is effective in increasing blood flow rate in gastric mucosa, protecting the mucosa of digestive tracts and promoting secretion of alkali, however, it has relatively week action to suppress the secretion of acid. The combined use of the compound with an acid secretion-suppressing type antiulcer agent enables the increase in the blood flow rate in gastric mucosa without influencing to acid secretion suppressing activity. The compounded drug has low toxicity and high safety. Preferably, 1-300mg/kg of the former compound and 0.1-300mg/kg of the acid secretion-suppressing type antiulcer agent are used in the objective agent.
PURPOSE: To obtain a cytomegalovirus(CMV) antigenemia-treating agent and the CMV infectious disease-treating agent which are little in side effects and high in safety. CONSTITUTION: The CMV antigenemia-preventing and a CMV-infectious disease- treating agent contain an anti-CMV human monoclonal antibody recognizing the envelope glycoprotein of the CMV and neutralizing the CMV, respectively. The anti-CMV human monoclonal antibody includes a human monoclonal antibody obtained by a hybridoma method using human antibody-producing cells and mouse myeloma cells subjected to an immunosensitization treatment using the envelop glycoprotein of CMV or by a EB virus-using transformation method. The anti-CMV human monoclonal antibody preferably recognizes a CMV envelope glycoprotein-B comprising the composite material of subunits having mol. wts. of 130000 dalton and 55000 dalton, and is preferably a human monoclonal antibody, regavirmab, produced by a hybridoma C23 (described in the patent specification of WO87/3602).
PURPOSE:To obtain a cosmetic product, containing a cardanol derivative having good beautifying and bleaching effects and potent suppressing effects on the hyaluronidase activity and on the active oxygen, having effects of beautifying and bleaching the skin, keeping the skin from chapping and keeping the skin well as glossy and tense. CONSTITUTION:A cosmetic product containing a cardanol derivative showen by formula I wherein, A is a 1-5C alkoxy, R is R1, R2 (R1 is CmHn-CH= CH-CpHq, and R2 is formula II; wherein CmHn and CpHq is a saturated or unsaturated hydrocarbon). As for the cardanol derivative of formula I is, e.g. 3-[8(Z)-pentadecenyl]methylphenyl ether, 3-[8(Z)-pentadecenyl]ethylphenyl ether, etc. The cardanols are obtained from cashew nut shell oil, etc. These compounds are safe in application to the skin. They can be used as a lotion, cream, etc.
LASIX® is a diuretic which is an anthranilic acid derivative. LASIX tablets for oral administration contain furosemide as the active ingredient and the following inactive ingredients: lactose monohydrate NF, magnesium stearate NF, starch NF, talc USP, and colloidal silicon dioxide NF. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. LASIX is available as white tablets for oral administration in dosage strengths of 20, 40 and 80mg. Furosemide is a white to off-white odorless crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids.

The CAS Registry Number is 54-31-9.

The structural formula is as follows: